Amgen (AMGN) Announces Meeting with U.S. FDA to Discuss ABP 501 BLA
Tweet Send to a Friend
Amgen (Nasdaq: AMGN) announced that the Company will discuss data supporting the ABP 501 Biologics License Application (BLA) with the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
